Feb 15, 2010 Seattle, WA
Seattle-based contract research organization ReachBio LLC announced today that Genetic Engineering and Biotechnology News (GEN) has published a Tutorial entitled “Predicting Drug-Induced Myelotoxicity”. This article explains the value of hematopoietic colony-forming cell (CFC) assays and ReachBio’s HemoRANK system for accurately predicting the myelotoxic potential of new drug candidates before they go to the clinic. It was co-authored by Dr. Emer Clarke, ReachBio’s Chief Scientific Officer, and Dr. Eric Atkinson, President of BroadReach BioSystems, Inc.
Click this link to see the article: